Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion

Matthew T. Bender, David A. Zarrin, Jessica K. Campos, Bowen Jiang, Arun Chandra, Chau D. Vo, Justin M. Caplan, Judy Huang, Rafael J. Tamargo, Li Mei Lin, Geoffrey P. Colby, Alexander L. Coon

Research output: Contribution to journalArticle

Abstract

Background: Dual antiplatelet therapy (DAT), most commonly with aspirin and Clopidogrel, is the standard of care for intracranial stenting, including flow diversion. Clopidogrel response varies by individual. Objective: To investigate the real-world precision of VerifyNow P2Y12 assessment (Accumetrics, San Diego, California) of Clopidogrel response. Methods: Using a prospectively-collected, IRB-approved cerebral aneurysm database 643 patients were identified who were treated with the Pipeline embolization device from 2011 to 2017. Patients with multiple P2Y12 assays drawn within a 24-h window were identified. A single patient could contribute multiple, independent sets. Levels drawn before a 5-d course of DAT and patients who received alternative antiplatelet agents were excluded. Therapeutic range was defined as platelet reaction units (PRU) 60-200. Results: A total of 1586 P2Y12 measurements were recorded; 293 (46%) patients had more than one assay. One hundred forty (22%) patients had multiple P2Y12 measurements within 24 h. These patients accounted for 230 independent 24-h sets. The average P2Y12 fluctuation across all sets was 35 points; the 25th, 50th, and 75th percentiles were 12, 26, and 48 points, respectively. Of the 230 24-h sets of P2Y12 assays, 76% remained within their original therapeutic category: 100 (43%) all therapeutic, 54 (23%) all hypo-responsive, and 21 (9%) all hyper-responsive. Twenty-four percent of patients fluctuated between therapeutic categories when multiple P2Y12 assessments were drawn within a 24-h period: 29 (13%) between hypo-response and therapeutic, 23 (10%) between hyper-response and therapeutic, and 3 (1%) between hypo-response and hyper-response. CONCLUSION: Our experience suggests P2Y12 is an often-imprecise measure, and this should be considered when utilizing P2Y12 levels for clinical decisions.

Original languageEnglish (US)
Pages (from-to)543-549
Number of pages7
JournalClinical Neurosurgery
Volume85
Issue number4
DOIs
StatePublished - Oct 1 2019

Fingerprint

clopidogrel
Intracranial Aneurysm
Therapeutics
Research Ethics Committees
Platelet Aggregation Inhibitors
Standard of Care
Aspirin

Keywords

  • Antiplatelet
  • Clopidogrel
  • Flow diversion
  • P2Y12
  • VerifyNow

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Bender, M. T., Zarrin, D. A., Campos, J. K., Jiang, B., Chandra, A., Vo, C. D., ... Coon, A. L. (2019). Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion. Clinical Neurosurgery, 85(4), 543-549. https://doi.org/10.1093/neuros/nyy395

Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion. / Bender, Matthew T.; Zarrin, David A.; Campos, Jessica K.; Jiang, Bowen; Chandra, Arun; Vo, Chau D.; Caplan, Justin M.; Huang, Judy; Tamargo, Rafael J.; Lin, Li Mei; Colby, Geoffrey P.; Coon, Alexander L.

In: Clinical Neurosurgery, Vol. 85, No. 4, 01.10.2019, p. 543-549.

Research output: Contribution to journalArticle

Bender, Matthew T. ; Zarrin, David A. ; Campos, Jessica K. ; Jiang, Bowen ; Chandra, Arun ; Vo, Chau D. ; Caplan, Justin M. ; Huang, Judy ; Tamargo, Rafael J. ; Lin, Li Mei ; Colby, Geoffrey P. ; Coon, Alexander L. / Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion. In: Clinical Neurosurgery. 2019 ; Vol. 85, No. 4. pp. 543-549.
@article{54c48eb28e7f482d8c8478bd47eb53a3,
title = "Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion",
abstract = "Background: Dual antiplatelet therapy (DAT), most commonly with aspirin and Clopidogrel, is the standard of care for intracranial stenting, including flow diversion. Clopidogrel response varies by individual. Objective: To investigate the real-world precision of VerifyNow P2Y12 assessment (Accumetrics, San Diego, California) of Clopidogrel response. Methods: Using a prospectively-collected, IRB-approved cerebral aneurysm database 643 patients were identified who were treated with the Pipeline embolization device from 2011 to 2017. Patients with multiple P2Y12 assays drawn within a 24-h window were identified. A single patient could contribute multiple, independent sets. Levels drawn before a 5-d course of DAT and patients who received alternative antiplatelet agents were excluded. Therapeutic range was defined as platelet reaction units (PRU) 60-200. Results: A total of 1586 P2Y12 measurements were recorded; 293 (46{\%}) patients had more than one assay. One hundred forty (22{\%}) patients had multiple P2Y12 measurements within 24 h. These patients accounted for 230 independent 24-h sets. The average P2Y12 fluctuation across all sets was 35 points; the 25th, 50th, and 75th percentiles were 12, 26, and 48 points, respectively. Of the 230 24-h sets of P2Y12 assays, 76{\%} remained within their original therapeutic category: 100 (43{\%}) all therapeutic, 54 (23{\%}) all hypo-responsive, and 21 (9{\%}) all hyper-responsive. Twenty-four percent of patients fluctuated between therapeutic categories when multiple P2Y12 assessments were drawn within a 24-h period: 29 (13{\%}) between hypo-response and therapeutic, 23 (10{\%}) between hyper-response and therapeutic, and 3 (1{\%}) between hypo-response and hyper-response. CONCLUSION: Our experience suggests P2Y12 is an often-imprecise measure, and this should be considered when utilizing P2Y12 levels for clinical decisions.",
keywords = "Antiplatelet, Clopidogrel, Flow diversion, P2Y12, VerifyNow",
author = "Bender, {Matthew T.} and Zarrin, {David A.} and Campos, {Jessica K.} and Bowen Jiang and Arun Chandra and Vo, {Chau D.} and Caplan, {Justin M.} and Judy Huang and Tamargo, {Rafael J.} and Lin, {Li Mei} and Colby, {Geoffrey P.} and Coon, {Alexander L.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1093/neuros/nyy395",
language = "English (US)",
volume = "85",
pages = "543--549",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion

AU - Bender, Matthew T.

AU - Zarrin, David A.

AU - Campos, Jessica K.

AU - Jiang, Bowen

AU - Chandra, Arun

AU - Vo, Chau D.

AU - Caplan, Justin M.

AU - Huang, Judy

AU - Tamargo, Rafael J.

AU - Lin, Li Mei

AU - Colby, Geoffrey P.

AU - Coon, Alexander L.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Background: Dual antiplatelet therapy (DAT), most commonly with aspirin and Clopidogrel, is the standard of care for intracranial stenting, including flow diversion. Clopidogrel response varies by individual. Objective: To investigate the real-world precision of VerifyNow P2Y12 assessment (Accumetrics, San Diego, California) of Clopidogrel response. Methods: Using a prospectively-collected, IRB-approved cerebral aneurysm database 643 patients were identified who were treated with the Pipeline embolization device from 2011 to 2017. Patients with multiple P2Y12 assays drawn within a 24-h window were identified. A single patient could contribute multiple, independent sets. Levels drawn before a 5-d course of DAT and patients who received alternative antiplatelet agents were excluded. Therapeutic range was defined as platelet reaction units (PRU) 60-200. Results: A total of 1586 P2Y12 measurements were recorded; 293 (46%) patients had more than one assay. One hundred forty (22%) patients had multiple P2Y12 measurements within 24 h. These patients accounted for 230 independent 24-h sets. The average P2Y12 fluctuation across all sets was 35 points; the 25th, 50th, and 75th percentiles were 12, 26, and 48 points, respectively. Of the 230 24-h sets of P2Y12 assays, 76% remained within their original therapeutic category: 100 (43%) all therapeutic, 54 (23%) all hypo-responsive, and 21 (9%) all hyper-responsive. Twenty-four percent of patients fluctuated between therapeutic categories when multiple P2Y12 assessments were drawn within a 24-h period: 29 (13%) between hypo-response and therapeutic, 23 (10%) between hyper-response and therapeutic, and 3 (1%) between hypo-response and hyper-response. CONCLUSION: Our experience suggests P2Y12 is an often-imprecise measure, and this should be considered when utilizing P2Y12 levels for clinical decisions.

AB - Background: Dual antiplatelet therapy (DAT), most commonly with aspirin and Clopidogrel, is the standard of care for intracranial stenting, including flow diversion. Clopidogrel response varies by individual. Objective: To investigate the real-world precision of VerifyNow P2Y12 assessment (Accumetrics, San Diego, California) of Clopidogrel response. Methods: Using a prospectively-collected, IRB-approved cerebral aneurysm database 643 patients were identified who were treated with the Pipeline embolization device from 2011 to 2017. Patients with multiple P2Y12 assays drawn within a 24-h window were identified. A single patient could contribute multiple, independent sets. Levels drawn before a 5-d course of DAT and patients who received alternative antiplatelet agents were excluded. Therapeutic range was defined as platelet reaction units (PRU) 60-200. Results: A total of 1586 P2Y12 measurements were recorded; 293 (46%) patients had more than one assay. One hundred forty (22%) patients had multiple P2Y12 measurements within 24 h. These patients accounted for 230 independent 24-h sets. The average P2Y12 fluctuation across all sets was 35 points; the 25th, 50th, and 75th percentiles were 12, 26, and 48 points, respectively. Of the 230 24-h sets of P2Y12 assays, 76% remained within their original therapeutic category: 100 (43%) all therapeutic, 54 (23%) all hypo-responsive, and 21 (9%) all hyper-responsive. Twenty-four percent of patients fluctuated between therapeutic categories when multiple P2Y12 assessments were drawn within a 24-h period: 29 (13%) between hypo-response and therapeutic, 23 (10%) between hyper-response and therapeutic, and 3 (1%) between hypo-response and hyper-response. CONCLUSION: Our experience suggests P2Y12 is an often-imprecise measure, and this should be considered when utilizing P2Y12 levels for clinical decisions.

KW - Antiplatelet

KW - Clopidogrel

KW - Flow diversion

KW - P2Y12

KW - VerifyNow

UR - http://www.scopus.com/inward/record.url?scp=85062774199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062774199&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyy395

DO - 10.1093/neuros/nyy395

M3 - Article

C2 - 30169782

AN - SCOPUS:85062774199

VL - 85

SP - 543

EP - 549

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -